Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash plus CVR
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $64.38M | $57.42M | $51.35M | $55.31M | $71.86M | $73.41M | $60.37M | $15.39M |
| Cost of Revenue | N/A | $40.62M | $63.39M | $193.66M | N/A | N/A | $715.00K | $6.03M |
| Gross Profit | $64.38M | $16.80M | $-12.05M | $-138.35M | $71.86M | $73.41M | $59.66M | $9.36M |
| Gross Margin | 100.00% | 29.26% | -23.46% | -250.12% | 100.00% | 100.00% | 98.82% | 60.81% |
| Operating Expenses | $111.33M | $72.84M | $79.91M | $119.44M | $369.48M | $325.33M | $298.41M | $269.48M |
| Operating Income | $-46.95M | $-56.03M | $-91.96M | $-257.78M | $-297.63M | $-251.91M | $-238.75M | $-260.12M |
| Operating Margin | -72.92% | -97.58% | -179.09% | -466.06% | -414.19% | -343.14% | -395.48% | -1690.65% |
| Net Income | $-56.42M | $-55.19M | $872.13M | $-199.43M | $-278.02M | $-236.46M | $-215.52M | $-285.40M |
| Net Margin | -87.63% | -96.11% | 1698.54% | -360.55% | -386.90% | -322.08% | -357.01% | -1854.97% |
| EPS (Basic) | $-1.15 | $-1.00 | $-1.26 | $-2.87 | $-4.46 | $-4.25 | $-3.99 | $-5.45 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |